---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031065"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:51:30.860561+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monopar Q3 net loss improves to $2.0M; MNPR-101 radiopharma on track for first-in-human Dec 2023

## Summary
- Net loss $2.0M ($0.14/share) vs $2.4M ($0.19) YoY; cash and equivalents $8.5M.
- MNPR-101 radiopharma program to enter first-in-human study possibly as early as December 2023.
- Camsirubicin Phase 1b at fifth dose cohort (650 mg/m^2); two patients showed tumor reductions of ~18% and 20%.
- CTOS data: 9 of 14 stable disease, no DLT; one patient with LVEF decrease being assessed for cardiotoxicity.
- Cash runway through November 2024; company expects to seek additional capital within 12 months.

## SEC filing metadata
- accession: 0001437749-23-031065
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774923031065/0001437749-23-031065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774923031065/mnpr20231030d_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031065
- JSON: https://secwatch.observer/filing/0001437749-23-031065.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031065.txt

## Key facts
- Earnings Releases
  Monopar Therapeutics reported third quarter ended September 30, 2023 results: net income Net loss for the third quarter of 2023 was $2.0 million or $0.14 per share, EPS $0.14 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: Net loss for the third quarter of 2023 was $2.0 million or $0.14 per share
  - EPS: $0.14 per share
  - Result: reported results
  source text: Monopar Therapeutics Inc. issued a press release announcing its financial results and summarized recent developments for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774923031065/0001437749-23-031065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.